A mutant BRAF V600E-specific immunohistochemical assay: correlation with molecular mutation status and clinical outcome in colorectal cancer

The B-type Raf kinase (BRAF) V600E mutation is a well-established biomarker for poor prognosis in metastatic colorectal cancer (mCRC) and is a highly attractive drug target. A barrier to the development of new therapies targeting BRAF V600E in mCRC is the low prevalence of mutations (approximately 1...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Target Oncol
Autors principals: Day, Fiona, Muranyi, Andrea, Singh, Shalini, Shanmugam, Kandavel, Williams, David, Byrne, David, Pham, Kym, Palmieri, Michelle, Tie, Jeanne, Grogan, Thomas, Gibbs, Peter, Sieber, Oliver, Waring, Paul, Desai, Jayesh
Format: Artigo
Idioma:Inglês
Publicat: Springer International Publishing 2014
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4363480/
https://ncbi.nlm.nih.gov/pubmed/24859797
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11523-014-0319-8
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars